Genomics in acute lymphoblastic leukaemia: Insights and treatment implications

Nature Reviews Clinical Oncology

Volumn 12, Issue 6, 2015, Pages 344-357

  Roberts, Kathryn G ^a   Mullighan, Charles G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; CRLF2 PROTEIN, HUMAN; CYTOKINE RECEPTOR; DNA; ERG PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEUPLOIDY; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RISK; CHROMOSOME 21; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; COPY NUMBER VARIATION; CRLF2 GENE; DIPLOIDY; EPIGENETICS; ERG GENE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HYPODIPLOIDY; JAK GENE; LEUKEMOGENESIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; T LYMPHOCYTE; TRANSCRIPTION REGULATION; ADOLESCENT; ADULT; CHILD; DNA SEQUENCE; GENETIC EPIGENESIS; GENETIC VARIATION; GENETICS; GENOMICS; INFANT; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; RECURRENT DISEASE; TUMOR GENE; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; DIPLOIDY; DNA, NEOPLASM; EPIGENESIS, GENETIC; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENES, NEOPLASM; GENETIC VARIATION; GENOMICS; HUMANS; INFANT; JANUS KINASES; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, CYTOKINE; RECURRENCE; SEQUENCE ANALYSIS, DNA; TRANS-ACTIVATORS; YOUNG ADULT;

EID: 84930179795     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.38     Document Type: Review

References (188)

1. Inaba, H., Greaves, M. & Mullighan, C. G. Acute lymphoblastic leukaemia. Lancet 381, 1943-1955 (2013).
2. Ko, R. H. et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium Study. J. Clin. Oncol. 28, 648-654 (2010).
3. Raetz, E. A. & Bhatla, T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia Hematology Am. Soc. Hematol. Educ. Program 2012, 129-136 (2012).
4. Stock, W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program. 2010, 21-29 (2010).
5. Mullighan, C. G. et al. Rearrangement of CRLF2 in B-progenitor and Down syndrome-Associated acute lymphoblastic leukemia. Nat. Genet. 41, 1243-1246 (2009).
6. Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007).
7. Mulligha n, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110-114 (2008).
8. Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470-80 (2009).
9. Mullighan, C. G. et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 106, 9414-9418 (2009).
10. Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235-239 (2011).
11. Papaemmanuil, E. et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat. Genet. 46, 116-125 (2014).
12. Kuiper, R. P. et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways in volved in lymphocyte differentiation and cell cycle progression. Leukemia 21, 1258-1266 (2007).
13. Perez-Garcia, A. et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 122, 2425-2432 (2013).
14. Tosello, V. et al. WT1 mutations in T-ALL. Blood 114, 1038-1045 (2009).
15. Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19, 368-371 (2013).
16. Van Vlierberghe, P. et al. ETV6 mutations in early immature human T cell leukemias. J. Exp. Med. 208, 2571-2579 (2011).
17. Van Vlierberghe, P. et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat. Genet. 42, 338-342 (2010).
18. Kawamata, N. et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 111, 776-784 (2008).
19. Zhang, J. e t al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
20. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242-252 (2013).
21. Roberts K. G.,et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia Cancer Cell 22 153-166 2012).
22. De Keersmaec ker, K. et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet. 45, 186-190 (2013).
23. Kalender Atak, Z. et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 9, e1003997 (2013).
24. Li, Y. et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508, 98-102 (2014).
25. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685-696 (2010).
26. Mardis, E. R. & Wilson, R. K. Cancer genome sequencing: a review. Hum. Mol. Genet. 18, R163-R168 (2009).
27. Biesecker, L. G. & Green, R. C. Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 370, 2418-2425 (2014).
28. Tri marchi, T. et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell 158, 593-606 (2014).
29. Ling, H., Fabbri, M. & Calin, G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847-865 (2013).
30. Rinn, J. L. & Chang, H. Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 81, 145-166 (2012).
31. Bonasio, R. & Shiekhattar, R. Regulation of transcription by long noncoding RNAs. Annu. Rev. Genet. 48, 433-455 (2014).
32. Ulitsky, I. & Bartel, D. P. lincRNAs: genomics, evolution, and mechanisms. Cell 154, 26-46 (2013).
33. Herranz, D. et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat. Med. 20, 1130-1137 (2014).
34. Mansour, M. R. et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014).
35. Harrison, C. J. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br. J. Haematol. 144, 147-156 (2009).
36. Harrison, C. J. & Foroni, L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev. Clin. Exp. Hematol. 6, 91-113 (2002).
37. Paulsson, K. & Johansson, B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 48, 637-660 (2009).
38. Harrison, C. J. et al. Three disti nct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br. J. Haematol. 125, 552-559 (2004).
39. Nachman, J. B. et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110, 1112-1115 (2007).
40. Raimondi, S. C. et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 98, 2715-2722 (2003).
41. Harrison, C. J. Acute lymphoblastic leukemia. Clin. Lab. Med. 31, 631-647 (2011).
42. Russell L. J.,et al. Deregulated expression of cytokine recept or gene, CRLF2, is involved in lymphoid transformation in B?-cell precursor acute lymphoblastic leukemia Blood, 114, 2688-2698, 2009).
43. Aifantis, I., Raetz, E. & Buonamici, S. Molecular pathogenesis of T?-cell leukaemia and lymphoma. Nat. Rev. Immunol. 8, 380-390 (2008).
44. Moorman, A. V. The clinical relevance of chromosomal and genomic abnormalities in B?-cell precursor acute lymphoblastic leukaemia. Blood Rev. 26, 123-135 (2012).
45. Bernt, K. M. & Hunger, S. P. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front. Oncol. 4, 54 (2014).
46. Moorman, A. V. et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALL XII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109, 3189-3197 (2007).
47. Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 10, 125-134 (2009).
48. Roberts, K. G. et al. Integrated genomic and mutational profiling of adolescent and young adult ALL Identifies a high frequency of BCR?-ABL1?-like ALL cases with very poor outcome [abstract]. Blood 122, 825 (2013).
49. Roberts, K. G. et al. Targetable kinase-Activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005-1015 (2014).
50. Mullighan, C. G. Genomic charact erization of childhood acute lymphoblastic leukemia. Semin. Hematol. 50, 314-324 (2013).
51. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008).
52. Yang, J. J. et al. Genome-wide cop y number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112, 4178-4183 (2008).
53. Kawamata, N. et al. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int. J. Oncol. 34, 1603-1612 (2009).
54. Safavi, S. et al. Loss of chromosomes is the primary event in near-haploid and low-hypodiploid acute lymphoblastic leukemia. Leukemia 27, 248-250 (2013).
55. Ma, X. et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-progenitor acute lymphoblastic leukemia. Nat. Commun. (in press).
56. Andersson, A. K. et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukaemias. Nat. Genet. http://dx.doi.org/10.1038/ng.3230.
57. Virely, C. et al. Hapl oinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 24, 1200-1204 (2010).
58. Dang, J., Mullighan, C. G., Phillips, L. A., Mehta, P. & Downing, J. R. Retroviral and chemical mutagenesis Identifies Pax5 as a tumor suppressor in B?-progenitor acute lymphoblastic leukemia. Blood 112, 1789 (2008).
59. Sc hjerven, H. et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat. Immunol. 14, 1073-1083 (2013).
60. Joshi, I. et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre?-B cells and progression to acute lymphoblastic leukemia. Nat. Immunol. 15, 294-304 (2014).
61. Nutt, S. L., Heavey, B., Rolink, A. G. & Busslinger, M. Commitment to the B?-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556-562 (1999).
62. Fortschegger, K., Anderl, S., Denk, D. & Strehl, S. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development. Mol. Cancer Res. 12, 595-606 (2014).
63. Kawamata, N., Pennella, M. A., Woo, J. L., Berk, A. J. & Koeffler, H. P. Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene 31, 966-977 (2012).
64. Nebral, K. et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23, 134-143 (2009).
65. Liu, G. J. et al. Pax5 loss imposes a reversible differentiation block in B?-progenitor acute lymphoblastic leukemia. Genes Dev. 28, 1337-1350 (2014).
66. Schwickert, T. A. et al. Stage-specific control of early B cell development by the transcription factor Ikaros. Nat. Immunol. 15, 283-293 (2014).
67. Churchman, M. et al. High content screening identifies synthetic lethality of retinoid receptor agonists in IKZF1-mutated BCR-ABL1 positive acute lymphoblastic leukemia. Blood 122, 172 (2013).
68. van der Veer, A. et al. IKZF1 status as a prognostic feature in BCR?-ABL1?-positive childhood ALL. Blood 123, 1691-1698 (2014).
69. Harvey, R. C. et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B?-progenitor acute lymphoblastic leukemia. Blood 115, 5312-5321 (2010).
70. Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503-514 (2012).
71. Paulsson, K. et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclu sive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 47, 26-33 (2008).
72. Wiemels, J. L. et al. Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia. Blood Cells Mol. Dis. 45, 186-191 (2010).
73. Irving, J. et al. Ras pathway mutations are highly prevalent in relapsed childhood acute lymphoblastic leukaemia, may act as relapse-dr ivers and confer sensitivity to MEK inhibition. Blood 124, 3420-3430 (2014).
74. van der Veer, A. et al. Independent prognostic value of BCR?-ABL1?-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B?-cell precursor ALL. Blood 122, 2622-2629 (2013).
75. Loh, M. L. et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood 121, 485-488 (2013).
76. Kiyokawa, N. et al. An analysis of Ph-like ALL in Japanese patients [abstract]. Blood 112, 352 (2013).
77. Pui, C. H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730-2741 (2009).
78. Roberts, K. G. et al. Outcomes of children with BCR?-ABL1?-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of m inimal residual disease. J. Clin. Oncol. 32, 3012-3020 (2014).
79. Weston, B. W. et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1?-PDGFRB?-positive acute lymphoblastic leukemia. J. Clin. Oncol. 31, e413-e416 (2013).
80. Lengline, E. et al. Successful tyrosine kinase inhibitor therapy in a refractory B?-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 98, e146-e148 (2013).
81. Schultz, K. R. et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J. Clin. Oncol. 27, 5175-5181 (2009).
82. Har vey, R. C. et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B?-precursor acute lymphoblastic leukemia (ALL) patients with a philadelphia chromosome-like ("Ph-like " or "BCR?-ABL1?-Like") signature for therapeutic targeting and clinical intervention [abstract]. Blood 122, 826 (2013).
83. Hertzberg, L. et al. Down syndrome acute lymphoblastic leukemia: a highly hete rogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the iBFM Study Group. Blood 115, 1006-1017 (2010).
84. Buitenkamp, T. D. et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 26, 2204-2211 (2012).
85. Yoda A.,et al Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 107, 252-257, 2010).
86. Shochat, C. et al. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood 124, 106-110 (2014).
87. Cario, G. et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non?-high?-risk precursor B?-cell acute lymph oblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115, 5393-5397 (2010).
88. Palmi, C. et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 10, 2245-2253 (2012).
89. Yamashita, Y. et al. IKZF1 and CRLF2 gene alterations correlate wi th poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatr. Blood Cancer 60, 1587-1592 (2013).
90. Attarbaschi, A. et al. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. Br. J. Haematol. 158, 772-777 (2012).
91. Chen, I. M. et al. Outcome mo deling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 119, 3512-3522 (2012).
92. Ensor, H. M. et al. Demog raphic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 117, 2129-2136 (2011).
93. Bercovich, D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 1484-1492 (2008).
94. Nikolaev, S. I. et al. Frequent ca ses of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat. Commun. 5, 4654 (2014).
95. Tasian, S. K. et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 120, 833-842 (2012).
96. Maude, S. L. et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120, 3510-3518 (2012).
97. Shochat, C. et al. Gain-of-function mutations in interleukin-7 receptor-Alpha (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208, 901-908 (2011).
98. Zenatti, P. P. et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 43, 932-939 (2011).
99. Treanor, L. M. et al. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J. Exp. Med. 211, 701-713 (2014).
100. Pui, C. H. et al. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood 75, 1170-1177 ( 1990).
101. Pui, C. H. et al. Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood 70, 247-253 (1987).
102. An, Q. et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc. Natl Acad. Sci. USA 105, 17050-17054 (2008).
103. Muhlbacher, V. et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 53, 524-536 (2014).
104. Mullighan, C. G. et al. ERG deletions define a novel subtype of B-progenitor acute lymphoblastic leukemia [abstract]. Blood 110, 691 (2007).
105. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
106. Marcucci G.,et al High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study J. Clin. Oncol. 25, 3337-3343, 2007)
107. Clappier, E. et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28, 70-77 (2014).
108. Moorman, A. V. et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109, 2327-2330 (2007).
109. Harrison, C. J. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28, 1015-1021 (2014).
110. Heerema, N. A. et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a repor t from the Children's Oncology Group. J. Clin. Oncol. 31, 3397-3402 (2013).
111. Moorman, A. V. et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children a nd adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J. Clin. Oncol. 31, 3389-3396 (2013).
112. Weng, A. P.et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
113. O'Neil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007).
114. Gutierrez, A. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647-650 (2009).
115. Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13, 1203-1210 (2007).
116. Coustan-Smith, E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147-156 (2009).
117. Neumann, M. et al. Clinica l and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2, e55 (2012).
118. Inukai, T. et al. Clinica l significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15 Br. J. Haematol. 156, 358-365 (2012).
119. Patrick, K. et al. Out come for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br. J. Haematol. 166, 421-424 (2014).
120. Wood, B. L. et al. T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children's Oncology Group ( COG) study AALL0434 [abstract]. Blood 124, 1 (2014).
121. Ntziachristos, P. et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298-303 (2012).
122. Della Gatta, G. et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat. Med. 18, 436-440 (2012).
123. Yan, L. et al. Clinical, immunophenotypic, cyto genetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica 97, 1708-1712 (2012).
124. Atak, Z. K. et al. Co mprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 9, e1003997 (2013).
125. Palomero, T. et al. NOTCH1 directly regulat es c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261-18266 (2006).
126. Figueroa, M. E. et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J. Clin. Invest. 123, 3099-3111 (2013).
127. Geng, H. et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-Acute lymphoblastic leukemia. Cancer Discov. 2, 1004-1023 (2012).
128. Milani, L. et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115, 1214-1225 (2010).
129. Schafer, E. et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood 115, 4798-4809 (2010).
130. Airoldi, I. et al. Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-Acute lymphoblastic leukemia cells. Cancer Res. 66, 3978-3980 (2006).
131. Batova, A. et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 57, 832-836 (1997).
132. Borssen, M. et al. Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS ONE 8, e65373 (2013).
133. Nakamura, M. et al. p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. Leukemia 13, 884-890 (1999).
134. Paulsson, K. et al. Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silen cing in high hyperdiploid acute lymphoblastic leukaemia. Br. J. Haematol. 144, 838-847 (2009).
135. Roman-Gomez, J. et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104, 2492-2498 (2004).
136. St umpel, D. J. et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 114, 5490-5498 (2009 ).
137. Stumpel, D. J. et al. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia 25, 429-439 (2011).
138. Taylor, K. H. et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 67, 2617-2625 (2007).
139. Yang, Y. et al. Aberrant methylation in promoter-Associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk. Res. 30, 98-102 (2006).
140. Figueroa, M. E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13-27 (2010).
141. Jaffe, J. D. et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45, 1386-1391 (2013).
142. Mar, B. G. et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat. Commun. 5, 3469 (2014).
143. Knoechel, B. et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 46, 364-370 (2014).
144. Roderick, J. E. et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123, 1040-1050 (2014).
145. Ntziachristos, P. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513-517 (2014).
146. Bhatia, K. P. et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 118, 1087-1093 (1995).
147. Hof, J. et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 29, 3185-3193 (2011).
148. Meyer, J. A. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45, 290-294 (2013).
149. Faham M.,et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia Blood, 120, 5173-5180, 2012).
150. Raphael, B. J., Dobson, J. R., Oesper, L. & Vandin, F. Identifying driver mutati ons in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med. 6, 5 (2014).
151. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013).
152. Marx, V. Cancer genomes: discerning drivers from passengers. Nat. Meth. 11, 375-379 (2014).
153. Ka ndoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
154. The Cancer Genome Atlas Research et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013).
155. Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
156. Xu, H. et al. Novel susceptibility variants at 10p12.31-122 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J. Natl Cancer Inst. 105, 733-742 (2013).
157. Perez-Andreu, V. et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. 45, 1494-1498 (2013).
158. Ya ng, J. J. et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 120, 4197-4204 (2012).
159. Yang, J. J. et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat. Genet. 43, 237-241 (2011).
160. Yang, W. et al. ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia 24, 894-896 (2010).
161. Yang, J. J. et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301, 393-403 (2009).
162. Trevino, L. R. et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1001-1005 (2009).
163. Migliorini, G. et al. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood 122, 3298-3307 (2013).
164. Sherborne, A. L. et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat. Genet. 42, 492-494 (2010).
165. Prasad, R. B. et al. Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood 115, 1765-1767 (2010).
166. Papaemmanuil, E. et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1006-1010 (2009).
167. Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226-1231 (2013).
168. Powell, B. C. et al. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr. Blood Cancer 60, E1-E3 (2013).
169. Dyer, M. J. et al. Immunoglobulin heavy chain (IGH) locus chromosomal tran slocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL): rare clinical curios or potent genetic drivers? Blood 115, 1490-1499 (2009).
170. Perez-Andreu V.,et al. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults Blood 125, 680-686, 2015).
171. Auer, F. et al. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547GA. Leukemia 5, 1136-1138 (2013).
172. Pui, C. H., Carroll, W. L., Meshinchi, S. & Arceci, R. J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29, 551-565 (2011).
173. Campana, D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr. Opin. Hematol. 19, 313-318 (2012).
174. Waanders, E. et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 25, 254-258 (2011).
175. Kuiper, R. P. et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 24, 1258-1264 (2010).
176. P almi, C. et al. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to " incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome ne gative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia".Haematologica 98, e164-e165 (2013).
177. Palmi, C. et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia Haematologica 98, 1226-1231 (2013).
178. Bhojwani, D. & Pui, C. H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 14, e205-e217 (2013).
179. Venn, N. C. et al. Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion. Leukemia 26, 1414-1416 (2012).
180. Meyer, J. A., Carroll, W. L. & Bhatla, T. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia Expert. Rev. Hematol. 6, 223-224 (2013).
181. Iacobucci, I. et al. Identifica tion and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Workin g Party (GIMEMA AL WP). Blood 114, 2159-2167 (2009).
182. Martinelli, G. et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival a nd high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J. Clin. Oncol. 27, 5202-5207 (2009).
183. Gaikwad, A. et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br. J. Haematol. 144, 930-932 (2009).
184. Kearney, L. et al. A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukaemia. Blood 113, 646-648 (2008).
185. Yoda, A. et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 107, 252-257 (2010).
186. Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189-195 (2011).
187. Blau, O. et al. Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia. Leuk. Res. 21, 721-729 (1997).
188. Gump, J., McGavran, L., Wei, Q. & Hunger, S. P. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 23, 416-469 (2001).